



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Anna-Karin Olsson, et al. Art Unit : 1646
Serial No. : 10/067,093 Examiner : Unknown
Filed : February 4, 2002
Title : HISTIDINE-RICH GLYCOPROTEIN

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
JUL 23 2002
TECH CENTER 1600/2900
p#4

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Information Disclosure Statement (1 page);
2. Form PTO-1449 (3 pages);
3. Copies of Cited References (52); and
4. A Return Postcard.

Please date stamp and mail the enclosed postcard.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: July 15, 2002

Ronald C. Lundquist
Ronald C. Lundquist, Ph.D.
Reg. No. 37,875

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60093218.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit 7-16-02
Trisha J. Anderson
Signature

Trisha J. Anderson
Typed or Printed Name of Person Signing Certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Anna-Karin Olsson, et al.
Serial No. : 10/067,093
Filed : February 4, 2002
Title : HISTIDINE-RICH GLYCOPROTEIN

Art Unit : 1646
Examiner : Unknown

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1000/2900

JUL 23 2002

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449, copies of which are enclosed.

This statement is being filed within three months of the filing date of the application or before the receipt of a first Office action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: July 15, 2002

Ronald C. Lundquist
Ronald C. Lundquist, Ph.D.
Reg. No. 37,875

Fish & Richardson P.C., P.A.
60 South Sixth Street
Suite 3300
Minneapolis, MN 55402
Telephone: (612) 335-5070
Facsimile: (612) 288-9696

60093148.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

Signature

7-16-02
Trisha J. Anderson

Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12389-003001	Application No. 10/067,093
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Anna-Karin Olsson, et al.	
		Filing Date February 4, 2002	Group Art Unit 1646

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	4,946,778	08/07/90	Ladner et al.			
	AB	5,545,806	08/13/96	Lonberg et al.			JUL 23 2002
	AC	5,569,825	10/29/96	Lonberg et al.			TECH CENTER 1600/2900
	AD	5,854,205	12/29/98	O'Reilly et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AE							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AF	GenBank Accession No. U32189 ✓
	AG	GenBank Accession No. AF194028 ✓
	AH	GenBank Accession No. AF194029 ✓
	AI	GenBank Accession No. NM_000412 ✓
	AJ ✓	Auerbach et al., "Assays for Angiogenesis: A Review," <u>Pharmac. Ther.</u> , 1991, 51:1-11
	AK ✓	Ausubel et al. (eds.), <u>Short Protocols in Molecular Biology</u> , 1992, Second Edition, Green Publishing Associates and John Wiley & Sons, New York, Chapter 11, pp. 11-1 – 11-54
	AL ✓	Beauchamp et al., "A New Procedure for the Synthesis of Polyethylene Glycol-Protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and α_2 -Macroglobulin," <u>Analytical Biochemistry</u> , 1983, 131:25-33
	AM ✓	Borza et al., "Domain Structure and Conformation of Histidine – Proline-Rich Glycoprotein," <u>Biochemistry</u> , 1996, 35:1925-1934
	AN ✓	Cole et al., "The EBV-Hybridoma Technique and its Application to Human Lung Cancer," <u>Monoclonal Antibodies and Cancer Therapy</u> , 1983, Alan R. Liss, Inc., pp. 77-96
	AO ✓	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens," <u>Proc. Natl. Acad. Sci. USA</u> , 1983, 80:2026-2030
	AP ✓	David and Reisfeld, "Protein Iodination with Solid State Lactoperoxidase," <u>Biochemistry</u> , 1974, 13(5):1014-1021
	AQ ✓	Dieffenbach et al. (eds.), <u>PCR Primer – A Laboratory Manual</u> , 1995, Cold Spring Harbor Laboratory Press (Table of Contents only)
	AR ✓	Dixelius et al., "Endostatin-induced tryosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis," <u>Blood</u> , 2000, 95(11):3403-3411
	AS ✓	Drasin and Sahud, "Blood-Type and Age Affect Human Plasma Levels of Histidine-Rich Glycoprotein in a Large Population," <u>Thromb. Res.</u> , 1996, 84(3):179-188

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12389-003001	Application No. 10/067,093
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Anna-Karin Olsson, et al.	
		Filing Date February 4, 2002	Group Art Unit 1646

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AT ✓	Friedlander et al., "Definition of Two Angiogenic Pathways by Distinct α_v Integrins," <i>Science</i> , 1995, 270:1500-1502
	AU ✓	Gerwins et al., "Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis," <i>Crit. Rev. Oncol./Hematol.</i> , 2000, 34:185-194
	AV ✓	Gilbert, <i>Developmental Biology</i> , 2000, Sixth Edition, Sinauer Associates, Inc., Sunderland, Massachusetts, Chapter 6, pp. 143-181
	AW ✓	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 1994, 7:13-21
	AX ✓	Heimburger et al., "Humanserumproteine mit hoher Affinität zu Carboxymethylcellulose," <i>Hoppe-Seyler's Z. Physiol. Chem.</i> , 1972, 353:1133-1140
	AY ✓	Hennis et al., "Identification and Genetic Analysis of a Common Molecular Variant of Histidine-rich Glycoprotein with a Difference of 2KD in Apparent Molecular Weight," <i>Thromb. Haemost.</i> , 1995, 74(6):1491-1496
	AZ ✓	Hennis et al., "An Amino Acid Polymorphism in Histidine-rich Glycoprotein (HRG) Explains 59% of the Variance in Plasma HRG Levels," <i>Thromb. Haemost.</i> , 1995, 74(6):1497-1500
	AAA ✓	Hulett and Parish, "Mutine histidine-rich glycoprotein: Cloning, characterization and cellular origin," <i>Immunol. Cell Biol.</i> , 2000, 78:280-287
	ABB ✓	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 1989, 246:1275-1281
	ACC ✓	Joki et al., "Continuous release of endostatin from microencapsulated engineered cells for tumor therapy," <i>Nature Biotech.</i> , 2001, 19:35-39
	ADD ✓	Kluszyński et al., "Zinc as a Cofactor for Heparin Neutralization by Histidine-rich Glycoprotein," <i>J. Biol. Chem.</i> , 1997, 272(21):13541-13547
	AEE ✓	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , 1975, 256:495-497
	AFF ✓	Koide et al., "The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III," <i>FEBS Lett.</i> , 1986, 194(2):242-244
	AGG ✓	Koide et al., "Amino Acid Sequence of Human Histidine-Rich Glycoprotein Derived from the Nucleotide Sequence of Its cDNA," <i>Biochemistry</i> , 1986, 25:2219-2225
	AHH ✓	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <i>Immunol. Today</i> , 1983, 4(3):72-79
	AII ✓	Kunkel, "Rapid and efficient site-specific mutagenesis without phenotypic selection," <i>Proc. Natl. Acad. Sci. USA</i> , 1985, 82:488-492
	AJJ ✓	Lijnen et al., "Heparin Binding Properties of Human Histidine-rich Glycoprotein," <i>J. Biol. Chem.</i> , 1983, 258(6):3803-3808
	AKK ✓	Matthews et al., "Enhanced Chemiluminescent Method for the Detection of DNA Dot-Hybridization Assays," <i>Analytical Biochemistry</i> , 1985, 151:205-209
	ALL ✓	Nygren, "Conjugation of Horseradish peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents," <i>J. Histochem. Cytochem.</i> , 1982, 30(5):407-412
	AMM ✓	Pain and Surolija, "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its use in Enzyme Immunoassays," <i>J. Immunol. Meth.</i> , 1981, 40:219-230
	ANN ✓	Peterson et al., "Histidine-rich Glycoprotein Modulation of the Anticoagulant Activity of Heparin," <i>J. Biol. Chem.</i> , 1987, 262(16):7567-7574

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12389-003001	Application No. 10/067,093
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Anna-Karin Olsson, et al.	
		Filing Date February 4, 2002	Group Art Unit 1646

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AOO	Read et al., "Local endostatin treatment of gliomas administered by microencapsulated producer cells," <u>Nature Biotech.</u> , 2001, 19:29-34
	APP	Rylatt et al., "Autorosette Inhibition Factor: Isolation and Properties of the Human Plasma Protein," <u>Eur. J. Biochem.</u> , 1981, 119:641-646
	AQQ	Sambrook et al. (eds.), <u>Molecular Cloning - A Laboratory Manual</u> , 1989, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 7.39-7.52
	ARR	Sambrook et al. (eds.), <u>Molecular Cloning - A Laboratory Manual</u> , 1989, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 16.1-17.44
/	ASS	Shigekiyo et al., "Congenital Histidine-Rich Glycoprotein Deficiency," <u>Thromb. Haemost.</u> , 1993, 70(2):263-265
/	ATR	Shigekiyo et al., "HRG Tokushima: Molecular and Cellular Characterization of Histidine-Rich Glycoprotein (HRG) Deficiency," <u>Blood</u> , 1998, 91:128-133
/	AUU	Simantov et al., "Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1," <u>J. Clin. Invest.</u> , 2001, 107:45-52
/	AVV	Sørensen et al., "Determination of the disulphide bridge arrangement of bovine histidine-rich glycoprotein," <u>FEBS Lett.</u> , 1993, 328(3):285-290
/	AWW	"Vascular Endothelial Growth Factor," <u>Mini-Reviews & Technical Information</u> , www.rndsystems.com , pp. 16-17
	AXX	Wennström et al., "The Platelet-derived Growth Factor β -Receptor Kinase Insert Confers Specific Signaling Properties to a Chimeric Fibroblast Growth Factor Receptor," <u>J. Biol. Chem.</u> , 1992, 267(19):13749-13756
/	AYY	Workman et al., "UKCCCR guidelines for the welfare of animals in experimental neoplasia," <u>Lab. Animals</u> , 1988, 22:195-201
/	AZZ	Zehnder and Leung, "Histidine-rich glycoprotein: Is there a role in hemostasis or immune function?" <u>J. Lab. Clin. Med.</u> , 1995, 125:682-683
	AAAA	Zola, <u>Monoclonal Antibodies: A Manual of Techniques</u> , 1987, CRC Press, Inc., Boca Raton, Florida, pp. 147-158

RECEIVED
 JUL 23 2002
 TECH CENTER 1600/2900

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	